Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
Open Access
- 11 January 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 69 (6), 1275-1283
- https://doi.org/10.1007/s00228-012-1466-4
Abstract
Purpose Numerous studies have investigated causes of warfarin dose variability in adults, whereas studies in children are limited both in numbers and size. Mechanism-based population modelling provides an opportunity to condense and propagate prior knowledge from one population to another. The main objectives with this study were to evaluate the predictive performance of a theoretically bridged adult warfarin model in children, and to compare accuracy in dose prediction relative to published warfarin algorithms for children. Method An adult population pharmacokinetic/pharmacodynamic (PK/PD) model for warfarin, with CYP2C9 and VKORC1 genotype, age and target international normalized ratio (INR) as dose predictors, was bridged to children using allometric scaling methods. Its predictive properties were evaluated in an external data set of children 0–18 years old, including comparison of dose prediction accuracy with three pharmacogenetics-based algorithms for children. Results Overall, the bridged model predicted INR response well in 64 warfarin-treated Swedish children (median age 4.3 years), but with a tendency to overpredict INR in children ≤2 years old. The bridged model predicted 20 of 49 children (41 %) within ± 20 % of actual maintenance dose (median age 7.2 years). In comparison, the published dosing algorithms predicted 33–41 % of the children within ±20 % of actual dose. Dose optimization with the bridged model based on up to three individual INR observations increased the proportion within ±20 % of actual dose to 70 %. Conclusion A mechanism-based population model developed on adult data provides a promising first step towards more individualized warfarin therapy in children.Keywords
This publication has 24 references indexed in Scilit:
- Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among childrenBlood, 2012
- Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirementBlood, 2012
- Old and new antithrombotic drugs in neonates and infantsSeminars in Fetal and Neonatal Medicine, 2011
- A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation TherapyClinical Pharmacology & Therapeutics, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Effect of the VKORC1 Genotype on Warfarin Dose Requirements in Japanese Pediatric PatientsDrug Metabolism and Pharmacokinetics, 2011
- In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypesBlood, 2010
- Knowledge‐driven approaches for the guidance of first‐in‐children dosingPediatric Anesthesia, 2010
- Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trialTrials, 2010